Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

S(unaudited, in thousands)ASSETSDecember 29, 2012June 30, 2012Current assets:Cash, cash equivalents and
short-term investments

$
78,201$
,760Restricted cash

17,773614Accounts receivable, net

119,85374,666Inventories

151,27378,444Prepaid expenses and other current assets

24,97912,582Total current assets

392,079228,066Property and equipment, net

111,72559,616Other intangible assets, net

39,40616,645Goodwill

10,90410,904Other non-current assets

14,82313,075Total assets

$
568,937$
328,306LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
22,558$
,098Accrued expenses and other liabilities

59,24849,944Capital lease obligations, current

11,650-Note payable

17,052-Credit line payable

40,75625,500Total current liabilities

251,264135,542Deferred gain on sale-leaseback

12,04912,722Convertible notes payable

23,350-Capital lease obligations, non-current

12,997-Other long-term liabilities

23,89912,391Total liabilities

323,559160,655Stockholders' equity:Common stock 

918515Additional paid-in capital 

1,424,1161,330,172Accumulated other comprehensive income

34,54829,538Accumulated deficit

(1,214,204)(1,192,574)Total stockholders' equity

245,378167,651Total liabilities and stockholders' equity

$
568,937$
328,306 

 


'/>"/>
SOURCE Oclaro, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
8. Kemwell Announces Successful Pre-NDA US FDA Inspection
9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
(Date:11/26/2014)... 2014   Royal Philips (NYSE: ... availability of its portfolio of diagnostic X-ray ... Opta[i] , ProGrade and PrimaryDiagnost[ii]. With new releases ... the U.S., and availability of all these solutions ... customers innovative solutions designed to meet the needs ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
... in Management of Transplant Recipients with Cancer, ... in post-transplant patients with cancer is challenging.,Clinicians must ... while,simultaneously monitoring the impact of chemotherapeutic agents on ... management of such patients will be,presented today at ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:11/27/2014)... "As a nurse I see patients every ... incontinence," said an inventor from Whiting, N.J. "I put ... to prevent leakage and keep them dry and comfortable." ... This prevents stains on pants, skirts and bottoms, which ... that the individual has time to get to the ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 ... a second language, new research suggests. But anyone who tries ... brain boost, the small study finds. The brain ... Ping Li, co-director of the Center for Brain, Behavior and ... Li said, that "the brain networks of the more successful ...
(Date:11/27/2014)... News) -- Most babies and young children don,t need ... and Drug Administration says. Over-the-counter (OTC) cold and ... than 2 because they could cause serious and potentially ... average about three colds a year, but children get ... might want to give them pain relievers, decongestants and ...
(Date:11/27/2014)... Thompson HealthDay Reporter WEDNESDAY, ... appears to be safe and produces an immune system response ... early clinical trial results reported by the U.S. National Institutes ... trial for the vaccine paves the way for field-testing it ... Leone as early as January, said Dr. Anthony Fauci, director ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... Roche Pharmaceuticals has granted a sub-license to Indian firm Hetero ... is the only drug known so far to have any ... virus. ,Hetero is based at Hyderabad and ... distributed across South East Asia and Africa. Commenting on the ...
... gearing up worldover, as the australian health minister ... be provided to all patients visiting queensland// hospital ... smoking following which the Australian Competition and Consumer ... sponsor anti-smoking advertising. ,Cigaretter manufacturers in ...
... and Resorts has banned smoking in the rooms, restaurants, bars ... Canada and the Caribbean from January 2006//., ,Guests will ... outdoor areas. , ,Westin said research among its customers ... room. , ,"Nobody likes to walk into a smoky ...
... has revealed that routine chest X-rays may serve to identify ... 172,000 Americans // are expected to be diagnosed with lung ... as this disease is invariably detected late. ,Earlier ... tumors, or patients were put through risky surgery as a ...
... and Finch showed the effect of childhood infections and ... diseases // . ,They collected mortality data ... and Switzerland from different years but ending with individuals ... was an important factor in treating childhood illness. ...
... Scientists in Scotland have discovered that an ordinary kitchen ... superbug, which is capable of resisting many // antibiotics. ... brand of the kitchen-scouring pad alone contains the cure ... according to reports can be grown on one particular ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: